Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
Clinical Performance Validation of Urine HPV Testing for Cervical Cancer Screening Among Women Living With HIV in South Africa
UNC Lineberger Comprehensive Cancer Center
300 participants
May 11, 2023
INTERVENTIONAL
Conditions
Summary
The purpose of this study explores the usefulness of urine samples for cervical cancer screening in human immunodeficiency virus (HIV)-infected women. Cervical cancer occurs when women are infected with the human papillomavirus (HPV), which can cause changes in the cells that lead to cervical precancer and, eventually, cervical cancer if untreated. However, urine HPV testing has not been well validated low- and middle-income country settings, with no data available to guide its use in HIV-infected women.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Human papillomavirus (HPV) testing in urine sample.
Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05413798